Related Experiment Video
Updated: Jun 12, 2026

Probiotic Studies in Neonatal Mice Using Gavage
Published on: January 27, 2019
Effect of Bifidobacterium animalis subsp lactis supplementation in preterm infants: a systematic review of randomized
Hania Szajewska1, Stefano Guandalini, Lorenzo Morelli
1Department of Paediatrics, Medical University of Warsaw, Warsaw, Poland. hania@ipgate.pl
Insights
Bifidobacterium animalis subsp lactis CNCM I-3446 supplementation shows potential benefits for preterm infants, improving gut health markers. Further research is needed to confirm clinical outcomes and safety.
Area of Science:
- Neonatal Medicine
- Microbiology
- Gastroenterology
Background:
- Preterm infants are vulnerable to gut dysbiosis and associated complications.
- Probiotic supplementation is being explored to modulate the gut microbiome in this population.
Purpose of the Study:
- To systematically review the efficacy and safety of Bifidobacterium animalis subsp lactis CNCM I-3446 in preterm infants.
- To update existing evidence on its impact on gut health and clinical outcomes.
Main Methods:
- A systematic search of Cochrane Library, MEDLINE, and conference proceedings for randomized controlled trials (RCTs).
- Inclusion criteria: RCTs in preterm infants (<37 weeks gestation and/or <2500g birth weight).
- Contacted manufacturer for unpublished data.
Main Results:
- Four RCTs (324 infants) were included.
- B lactis increased fecal bifidobacteria, reduced Enterobacteriaceae and Clostridium spp., lowered stool pH and fecal calprotectin.
- Increased fecal IgA and SCFAs, decreased intestinal permeability; no significant effect on necrotizing enterocolitis, sepsis, or antibiotic use.
- Some effects on anthropometric parameters noted; no adverse events reported.
Conclusions:
- B lactis supplementation shows encouraging evidence for beneficial effects in preterm infants.
- Further studies are necessary to confirm clinically relevant outcomes and long-term safety.
Objective:
To systematically evaluate and update evidence on the efficacy and safety of Bifidobacterium animalis subsp lactis CNCM I-3446 supplementation in preterm infants.
Materials And Methods:
The Cochrane Library and MEDLINE databases and major pediatric conference proceedings were searched in December 2008 for randomized controlled trials (RCTs). The company that manufactures B lactis was contacted for unpublished data. The review was restricted to RCTs performed in preterm infants <37 weeks of gestation and/or with a birth weight <2500 g.
Results:
Four RCTs involving 324 infants met the inclusion criteria. Compared with controls, B lactis supplementation has the potential to increase fecal bifidobacteria counts and to reduce Enterobacteriaceae and Clostridium spp counts. It also can reduce stool pH and fecal calprotectin concentrations, increase fecal immunoglobulin A and short-chain fatty acid concentrations, and decrease intestinal permeability. Compared with controls, B lactis supplementation had no effect on the risk of necrotizing enterocolitis stage > or = 2 (3 RCTs, n = 293, risk ratio [RR] 0.53, 95% CI 0.16-1.83), risk of sepsis (2 RCTs, 397 cultures, RR 0.6, 95% CI 0.07-5.2), and use of antibiotics (2 RCTs, n = 255, RR 0.67, 95% CI 0.28-1.62). The power of these studies, however, does not allow for a definitive statement regarding a reduced risk of necrotizing enterocolitis. B lactis supplementation did have some effects on anthropometric parameters. No adverse events associated with B lactis supplementation were reported.
Conclusions:
Evidence regarding the potential beneficial effects of B lactis supplementation in preterm infants is encouraging. Further studies to assess clinically relevant outcomes are needed.
Related Concept Videos
Development of Human Microbiota
Development of the Oral Microbiota
Microbiota Modulation by Antibiotics
Probiotics
Anatomy of the Intestines
Small Intestines
The small intestine is an ~7 meter-long tube with an inner diameter of just 2.5 cm. Since most nutrients are absorbed here, the inner lining of the small...
